West Pharmaceutical Services

WST Health Care Market cap $25.0B as of Sep 14, 2026 16:02 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Jul 23, 2026

Revenue$0.87B +14% year over year

Gross profit$0.33B 38% margin

Operating profit$0.18B 21% margin

Net profit$0.15B 18% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	0.87	100%	+14%
Proprietary products	0.72	83%	+17%
West vantage	0.15	17%	+2%
Cost of revenue	−0.54	62%
Gross profit	0.33	38% margin	+2pp
R&D	−0.02	2%	+0pp
SG&A	−0.12	13%	+1pp
Other	−0.01	2%	+0pp
Operating profit	0.18	21% margin	+0pp
Other income, net	0.01
Tax	−0.03
Net profit	0.15	18% margin	+0pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	0.85	100%	+21%
Proprietary products	0.69	82%	+23%
West vantage	0.15	18%	+12%
Cost of revenue	−0.55	65%
Gross profit	0.30	35% margin	+2pp
R&D	−0.02	2%	+0pp
SG&A	−0.10	12%	−1pp
Operating profit	0.18	21% margin	+6pp
Other income, net	0.01
Tax	−0.04
Net profit	0.14	16% margin	+4pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	0.81	100%	+8%
Proprietary products	0.66	82%	+8%
Contract manufactured	0.14	18%	+6%
Cost of revenue	−0.50	62%
Gross profit	0.30	38% margin	+1pp
R&D	−0.02	3%	+0pp
SG&A	−0.11	13%	+2pp
Other	−0.02	2%	+0pp
Operating profit	0.16	19% margin	−2pp
Other income, net	0.01
Tax	−0.03
Net profit	0.13	16% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	0.81	100%	+8%
Proprietary products	0.65	80%	+8%
Contract manufactured	0.16	20%	+8%
Cost of revenue	−0.51	63%
Gross profit	0.29	37% margin	+1pp
R&D	−0.02	2%	+0pp
SG&A	−0.10	13%	+2pp
Other	−0.01	1%	+0pp
Operating profit	0.17	21% margin	−1pp
Other income, net	0.01
Tax	−0.03
Net profit	0.14	17% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Jul 23, 2026 Operating margin 21% Net profit $0.15B	Apr 1 – Jun 30, 2026	Jul 23, 2026	$0.87B	+14%	21%	$0.15B	18%
Q1 FY26 Jan 1 – Mar 31, 2026 reported Apr 23, 2026 Operating margin 21% Net profit $0.14B	Jan 1 – Mar 31, 2026	Apr 23, 2026	$0.85B	+21%	21%	$0.14B	16%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 17, 2026 Operating margin 19% Net profit $0.13B	Oct 1 – Dec 31, 2025	Feb 17, 2026	$0.81B	+8%	19%	$0.13B	16%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Oct 23, 2025 Operating margin 21% Net profit $0.14B	Jul 1 – Sep 30, 2025	Oct 23, 2025	$0.81B	+8%	21%	$0.14B	17%